Fundraising FAQs
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Search
Search results
Positive early findings from ProQR trial of USH2A therapy
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.